SanBio Company Limited (TYO:4592)
Japan flag Japan · Delayed Price · Currency is JPY
2,695.00
-26.00 (-0.96%)
Aug 15, 2025, 3:30 PM JST

SanBio Company Company Description

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system.

The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan.

Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.

The company was founded in 2001 and is headquartered in Tokyo, Japan.

SanBio Company Limited
CountryJapan
Founded2001
IndustryBiotechnology
SectorHealthcare
Employees29
CEOKeita Mori

Contact Details

Address:
St. Luke Tower
Tokyo, 104-0044
Japan
Phone81 3 6264 3481
Websitesanbio.com

Stock Details

Ticker Symbol4592
ExchangeTokyo Stock Exchange
Stock TypeCommon Stock
Fiscal YearFebruary - January
Reporting CurrencyJPY
ISIN NumberJP3336750009
SIC Code2836

Key Executives

NamePosition
Keita MoriChief Executive Officer